Indication

Advanced Lymphoid Leukemia

1 clinical trial

1 product

Clinical trial

Long-term Follow-up Study of Patients Who Have Previously Been Exposed to UCART19 (Allogeneic Engineered T-cells Expressing a Lentiviral-based Anti-CD19 Chimeric Antigen Receptor)

Status: Active (not recruiting), Estimated PCD: 2025-02-01

Product